The gut: The forgotten organ in Uremia?

Blood Purification

Volumn 29, Issue 2, 2010, Pages 130-136

  Schepers, Eva ^a   Glorieux, Griet ^a   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Gut; P Cresol; Uremia; Uremic retention solutes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AST 120; INDOLE DERIVATIVE; PHENOL DERIVATIVE; PREBIOTIC AGENT; PROBIOTIC AGENT; UREMIC TOXIN;

DIETARY INTAKE; HEMODIALYSIS; HUMAN; INTESTINE; MALNUTRITION; NONHUMAN; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; UREMIA;

BACTERIA; BIOTRANSFORMATION; CARBON; CARDIOVASCULAR DISEASES; DIGESTION; FERMENTATION; GASTROINTESTINAL CONTENTS; GLOMERULAR FILTRATION RATE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INDOLES; INTESTINAL ABSORPTION; INTESTINES; OXIDES; PERITONEAL DIALYSIS; PHENOLS; PREBIOTICS; PROBIOTICS; RENAL DIALYSIS; TOXINS, BIOLOGICAL; UREMIA;

EID: 77749318546     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000245639     Document Type: Review

References (53)

1. Vanholder R, De Smet R, Glorieux G, et al: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943.
2. Vanholder RC, Ringoir SM: Adequacy of dialysis: a critical analysis. Kidney Int 1992; 42: 540-558.
3. Martin AK: The origin of urinary aromatic compounds excreted by ruminants. 3. The metabolism of phenolic compounds to simple phenols. Br J Nutr 1982; 48: 497-507.
4. Vanholder R, De Smet R, Lesaffer G: p-Cresol: a toxin revealing many neglected but relevant aspects of uraemic toxicity. Nephrol Dial Transplant 1999; 14: 2813-2815.
5. Hanioka H, Hamamura M, Kakino K, et al: Dog liver microsomal P450 enzyme-mediated toluene biotransformation. Xenobiotica 1995; 25: 1207-1217.
6. Madyastha KM, Raj CP: Evidence for the formation of a known toxin, p-cresol, from menthofuran. Biochem Biophys Res Commun 1991; 177: 440-446.
7. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996; 74: 349-355.
8. Guarner F, Malagelada JR: Gut flora in health and disease. Lancet 2003; 361: 512-519.
9. Yokoyama MT, Tabori C, Miller ER, Hogberg MG: The effects of antibiotics in the weanling pig diet on growth and the excretion of volatile phenolic and aromatic bacterial metabolites. Am J Clin Nutr 1982; 35:1417-1424.
10. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Impairment of small intestinal protein assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept. Am J Clin Nutr 2004; 80: 1536-1543.
11. Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P: Evidence for impaired assimilation of protein in chronic renal failure. Kidney Int 2003; 64: 2196-2203.
12. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H: Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann NY Acad Sci 2005; 1043: 461-466.
13. Uribarri J, Stirban A, Sander D, et al: Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 2007; 30: 2579-2582.
14. Koschinsky T, He CJ, Mitsuhashi T, et al: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997; 94: 6474-6479.
15. Bone E, Tamm A, Hill M: The production of urinary phenols by gut bacteria and their possible role in the causation of large bowel cancer. Am J Clin Nutr 1976; 29: 1448-1454.
16. De Smet R, David F, Sandra P, et al: A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 1998; 278: 1-21.
17. Martinez AW, Recht NS, Hostetter TH, Meyer TW: Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16: 3430-3436.
18. Pham NM, Recht NS, Hostetter TH, Meyer TW: Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol 2008; 3: 85-90.
19. Glorieux G, Helling R, Henle T, et al: In vitro evidence for immune activating effect of specific AGE structures retained in uremia. Kidney Int 2004; 66: 1873-1880.
20. Witko-Sarsat V, Friedlander M, Nguyen KT, et al: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532.
21. Schwedler SB, Metzger T, Schinzel R, Wanner C: Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002; 62: 301-310.
22. Roberts MA, Thomas MC, Fernando D, Macmillan N, Power DA, Ierino FL: Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. Nephrol Dial Transplant 2006; 21: 1611-1617.
23. Meerwaldt R, Lutgers HL, Links TP, et al: Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007; 30: 107-112.
24. Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R: p-Cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007; 22: 592-596.
25. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y: Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087.
26. Meijers BK, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, Evenepoel P: Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73: 1174-1180.
27. De Smet R, Van Kaer J, Van Vlem B, et al: Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chem 2003; 49: 470-478.
28. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003; 64: 2238-2243.
29. Vanholder R, De Smet R, Waterloos MA, et al: Mechanisms of uremic inhibition of phagocyte reactive species production: characterization of the role of p-cresol. Kidney Int 1995; 47: 510-517.
30. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T: Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 2003; 63: 1671-1680.
31. Dou L, Bertrand E, Cerini C, et al: The uremic solutes p-cresol and indoxylsulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451.
32. Nii-Kono T, Iwasaki Y, Uchida M, et al: Indoxylsulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 2007; 71: 738-743.
33. Motojima M, Nishijima F, Ikoma M, et al: Role for 'uremic toxin' in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991; 40: 461-469.
34. Perl J, Bargman JM: The importance of residual kidney function for patients on dialysis: a critical review. Am J Kidney Dis 2009; 53: 1068-1081.
35. Ueda H, Shibahara N, Takagi S, Inoue T, Katsuoka Y: AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial 2007; 11: 189-195.
36. Ueda H, Shibahara N, Takagi S, Inoue T, Katsuoka Y: AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 2008; 30: 856-860.
37. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056.
38. Meert N, Eloot S, Waterloos MA, et al: Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant 2009; 24: 562-570.
39. Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, Vanholder R: Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000; 15: 50-57.
40. Geypens B, Claus D, Evenepoel P, et al: Influence of dietary protein supplements on the formation of bacterial metabolites in the colon. Gut 1997; 41: 70-76.
41. Ling WH, Hanninen O: Shifting from a conventional diet to an uncooked vegan diet reversibly alters fecal hydrolytic activities in humans. J Nutr 1992; 122: 924-930.
42. Bliss DZ, Stein TP, Schleifer CR, Settle RG: Supplementation with gum arabic fiber increases fecal nitrogen excretion and lowers serum urea nitrogen concentration in chronic renal failure patients consuming a low-protein diet. Am J Clin Nutr 1996; 63: 392-398.
43. De Preter, V, Vanhoutte T, Huys G, et al: Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol Gastrointest Liver Physiol 2007; 292:G358-G368.
44. De Preter V, Coopmans T, Rutgeerts P, Verbeke K: Influence of long-term administration of lactulose and Saccharomyces boulardii on the colonic generation of phenolic compounds in healthy human subjects. J Am Coll Nutr 2006; 25: 541-549.
45. Birkett A, Muir J, Phillips J, Jones G, O'Dea K: Resistant starch lowers fecal concentrations of ammonia and phenols in humans. Am J Clin Nutr 1996; 63: 766-772.
46. Taki K, Takayama F, Niwa T: Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr 2005; 15: 77-80.
47. Ranganathan N, Patel BG, Ranganathan P, et al: In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease. ASAIO J 2006; 52: 70-79.
48. Chow KM, Liu ZC, Prakash S, Chang TM: Free and microencapsulated Lactobacillus and effects of metabolic induction on urea removal. Artif Cells Blood Substit Immobil Biotechnol 2003; 31: 425-434.
49. Niwa T, Ise M, Miyazaki T, Meada K: Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. Nephron 1993; 65: 82-87.
50. Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N: A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006; 47: 565-577.
51. Vanholder R, Meert N, Van Biesen W, et al: Why do patients on peritoneal dialysis have low blood levels of protein-bound solutes? Nat Clin Pract Nephrol 2009; 5: 130-131.
52. Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y: Superior dialytic clearance of beta(2)-microglobulin and p-cresol by highflux hemodialysis as compared to peritoneal dialysis. Kidney Int 2006; 70: 794-799.
53. Lameire N, Vanholder R, De Smet R: Uremic toxins and peritoneal dialysis. Kidney Int Suppl 2001; 78:S292-S297.